Zenith Study

Study for patients with chronic kidney disease and high proteinuria.

About

Zenith is A Phase III, Randomised, Multicentre, Double-blind Study to Evaluate the Efficacy, Safety, and Tolerability of Zibotentan/Dapagliflozin Compared to Dapagliflozin alone in
Participants with Chronic Kidney Disease and High Proteinuria

Eligibility

• Are 18 years of age or older

• Have been diagnosed with chronic kidney disease

• Have high proteinuria

**There are other requirements for taking part in this study.**

If you qualify, you may receive at no cost: • Close care and follow-up throughout the study. Participants will be compensated for taking part in the study

If you’re interested in participating in one of our Research Studies:

Call

303-232-3366

ext 2150, 2170 or 2190